HUC3-637 not checked

Huons Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Ophthalmic solution instilled directly into the eye (topical ocular administration)”In the company’s words, NCT07335211 on ClinicalTrials.gov
Tested for
Primary Open Angle Glaucoma (POAG), Ocular Hypertension
Main trialPhase 3
“A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension”In the company’s words, NCT07335211 on ClinicalTrials.gov

Other drugs for Primary Open Angle Glaucoma (POAG)

All 16 drugs for Primary Open Angle Glaucoma (POAG)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Nov 2027 Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow HUC3-637

Following is part of Solo: you see every change to HUC3-637 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in